Medpace Revises FY22 Outlook On Foreign Exchange Impact

  • Medpace Holdings Inc's MEDP Q2 revenue increased 26.2% Y/Y to $351.2 million, beating the consensus of $344.02 million. On a constant currency organic basis, revenue increased 27.7%.
  • As of March 31, 2022, the Backlog grew 24.4% to $2.2 billion. Net new business awards were $450.6 million, representing a net book-to-bill ratio of 1.28x.
  • EBITDA increased 42% to $68.1 million or 19.4% of revenue, compared to $47.9 million, or 17.2% of revenue a year ago.
  • Medpace posted EPS of $1.46, up from $1.06 a year ago and beating the consensus of $1.31.
  • Financial Guidance: Medpace reaffirmed FY22 revenue of $1.405 billion - $1.435 billion versus the prior guidance of $1.4 billion - $1.46 billion and the consensus of $1.40 billion.
  • EBITDA is expected to be $268 million - $280 million versus the previous guidance of $262 million - $278 million. 
  • The revised forecast includes an additional foreign exchange headwind on revenue of approximately $4 million and a tailwind on EBITDA of approximately $3 million.
  • Medpace expects EPS of $6.07 - $6.36 compared to prior guidance of $5.72 - $6.06 and the consensus of $5.82.
  • Price Action: MEDP shares closed 0.28% higher at $167.50 during the after-market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!